iCAD (NASDAQ:ICAD) Stock Passes Above 200 Day Moving Average of $1.50

iCAD, Inc. (NASDAQ:ICAD) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.50 and traded as high as $1.72. iCAD shares last traded at $1.66, with a volume of 115,672 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded iCAD from a “sell” rating to a “hold” rating in a report on Thursday, August 22nd.

iCAD Stock Up 2.8 %

The stock has a market capitalization of $44.06 million, a price-to-earnings ratio of -13.83 and a beta of 1.51. The business’s 50-day moving average is $1.48 and its two-hundred day moving average is $1.50.

iCAD (NASDAQ:ICAD) last announced its quarterly earnings data on Tuesday, August 13th. The technology company reported ($0.07) earnings per share (EPS) for the quarter. iCAD had a negative net margin of 15.67% and a negative return on equity of 13.59%. The firm had revenue of $5.03 million during the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC grew its holdings in shares of iCAD by 55.6% during the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock worth $34,000 after purchasing an additional 7,604 shares during the period. Perritt Capital Management Inc. boosted its position in shares of iCAD by 7.5% during the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock worth $225,000 after purchasing an additional 9,717 shares during the period. Perritt Capital Management Inc increased its holdings in iCAD by 14.2% in the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock valued at $208,000 after purchasing an additional 19,917 shares during the last quarter. First Eagle Investment Management LLC raised its position in iCAD by 3.2% in the first quarter. First Eagle Investment Management LLC now owns 701,525 shares of the technology company’s stock valued at $1,129,000 after purchasing an additional 22,000 shares during the period. Finally, Salem Investment Counselors Inc. acquired a new stake in iCAD in the 1st quarter valued at about $119,000. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.